On June 5, 2026 GlyTherix reported the grant of a Canadian patent covering its antibody-drug conjugate (ADC) technology, marking another important milestone in the expansion of the company’s global intellectual property portfolio.
The Canadian patent strengthens protection for GlyTherix’s proprietary ADC platform in a strategically important market and reinforces the company’s commitment to building a robust international patent estate around its innovative oncology programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this latest grant, GlyTherix continues to advance the global protection of its technology, enhancing the long-term value of its ADC assets and supporting future development and partnering opportunities.

Strong intellectual property protection is a critical component of successful drug development, and the Canadian patent provides further validation of the novelty and potential of GlyTherix’s targeted cancer therapy approach.

The continued expansion of GlyTherix’s patent portfolio positions GlyTherix to maximise the impact and commercial potential of its technology for patients and stakeholders worldwide.

(Press release, Glytherix, JUN 5, 2026, View Source [SID1234666465])